Detalles de la búsqueda
1.
Early Ultrasound Response and Progressive Transmural Remission After Treatment With Ustekinumab in Crohn's Disease.
Clin Gastroenterol Hepatol
; 21(1): 153-163.e12, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35842121
2.
Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study.
Ann Rheum Dis
; 75(10): 1763-9, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26590174
3.
Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study.
Clin Exp Rheumatol
; 34(3): 489-99, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26966919
4.
Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study.
BMC Musculoskelet Disord
; 16: 176, 2015 Jul 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-26228643
5.
Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST.
Aliment Pharmacol Ther
; 59(2): 175-185, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38036946
6.
Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial.
Ann Rheum Dis
; 72(8): 1287-94, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22915624
7.
Retention and clinical response to abatacept in patients with rheumatoid arthritis: an Italian perspective.
Clin Exp Rheumatol
; 36(5): 935-936, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29600933
8.
Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: Results up to Week 104 of the STARDUST trial.
United European Gastroenterol J
; 11(5): 410-422, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37139642
9.
Real-world outcomes associated with switching to anti-TNFs versus other biologics in Crohn's Disease patients: A retrospective analysis using German claims data.
Therap Adv Gastroenterol
; 15: 17562848221130554, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36353736
10.
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
Lancet Gastroenterol Hepatol
; 7(4): 294-306, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35120656
11.
Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study.
Ann Rheum Dis
; 70(11): 2003-7, 2011 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-21914628
12.
Correction to: Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study.
Clin Rheumatol
; 38(5): 1535, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30972577
13.
Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study.
Clin Rheumatol
; 38(5): 1413-1424, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-30790095
14.
Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial.
RMD Open
; 5(1): e000934, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31245054
15.
Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study.
RMD Open
; 4(1): e000564, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29657830
16.
Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis.
Clin Rheumatol
; 36(12): 2655-2665, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-28822046
17.
Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study.
RMD Open
; 3(1): e000345, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28243468
18.
Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study.
RMD Open
; 3(2): e000538, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-29435360
19.
The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study.
Joint Bone Spine
; 84(5): 571-576, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28043761
20.
Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study.
RMD Open
; 2(1): e000228, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26925253